A 32-year-old woman is diagnosed with systemic lupus erythematosus based on clinical and serological criteria. Which of the following is the most common autoantibody found in SLE?

Explanation

## Autoantibodies in Systemic Lupus Erythematosus **Key Point:** Anti-dsDNA (anti-double-stranded DNA) antibodies are the most common autoantibodies in SLE, present in 60–70% of SLE patients, and are highly specific for SLE diagnosis. ### Prevalence and Specificity of SLE Autoantibodies | Autoantibody | Prevalence in SLE | Specificity for SLE | Clinical Significance | |--------------|-------------------|-------------------|----------------------| | **Anti-dsDNA** | **60–70%** | **Very high (95–98%)** | **Lupus nephritis, disease activity** | | ANA (any pattern) | 95–98% | Low (present in many conditions) | Screening test, high sensitivity | | Anti-Sm | 20–30% | Very high (99%) | Diagnostic criterion, rare in other diseases | | Anti-histone | 50–60% | Moderate (drug-induced lupus) | Drug-induced SLE, less specific | | Anti-centromere | 5–10% | Moderate (also in scleroderma) | Limited SLE association | | Anti-Ro/SSA | 40–60% | Moderate (also in Sjögren's) | Neonatal lupus, photosensitivity | | Anti-La/SSB | 20–40% | High (Sjögren's association) | Sjögren's overlap | **High-Yield:** Although anti-Sm is more specific (99%) for SLE, anti-dsDNA is more common (60–70% vs. 20–30%), making it the **most common** autoantibody. ### Clinical Correlations **Clinical Pearl:** Anti-dsDNA antibodies correlate with: - **Lupus nephritis:** Presence of anti-dsDNA strongly predicts renal involvement - **Disease activity:** Titers fluctuate with disease flares; rising titers often precede clinical exacerbation - **Complement consumption:** High anti-dsDNA often accompanies low C3 and C4 levels - **Serositis and vasculitis:** Associated with systemic manifestations ### Pathogenic Mechanism Anti-dsDNA antibodies: 1. Form immune complexes with circulating dsDNA 2. Deposit in glomerular basement membrane and other tissues 3. Activate complement (classical pathway) 4. Trigger inflammation via Fc receptor engagement 5. Cross-react with nucleosomal antigens and glomerular components **Warning:** Do not confuse anti-dsDNA with anti-ssDNA (single-stranded DNA). Anti-ssDNA is less specific and less clinically significant. ### SLE Diagnostic Criteria Integration Anti-dsDNA positivity is one of the **EULAR/ACR 2019 classification criteria** for SLE: - Anti-dsDNA (or anti-Sm) antibodies at medium or high titer = 6 points (sufficient for SLE diagnosis if combined with other criteria) **Mnemonic: "dsDNA = Disease Specific DNA"** - **d** = Double-stranded (more specific than single-stranded) - **s** = Specific for SLE (95–98% specificity) - **DNA** = Diagnostic marker for lupus nephritis and disease activity ### Why Not the Other Options? **Anti-Sm antibodies:** - More specific (99%) but less common (20–30%) - Rarely found outside SLE - Diagnostic but not the most frequent **Anti-histone antibodies:** - Common in drug-induced lupus (>95%) - Present in 50–60% of idiopathic SLE - Less specific than anti-dsDNA - Associated with milder disease **Anti-centromere antibodies:** - Rare in SLE (5–10%) - More common in limited cutaneous systemic sclerosis (LCSS) - Not a primary SLE marker